RxDoctor Payments Data

Peter Ang, MD

Internal Medicine · Huntsville, TXNPI 1134186331

Payments from drug & device makers

$2,061in general payments, 2019–2025

Across 135 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$301
  • AstraZeneca$296
  • GSK$282
  • Astellas Pharma US Inc$164
  • Amgen$164
  • Lilly USA, LLC$162
  • plus $691 from 10 others

What the payments were for

  • Food & beverage$2,061100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,061 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$63,226
Medicare patients
364
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$167,827
EliquisApixaban139$142,017
OzempicSemaglutide129$138,911
JanuviaSitagliptin Phosphate83$96,264
MyrbetriqMirabegron54$41,734
XareltoRivaroxaban31$30,712
Tresiba Flextouch U-100Insulin Degludec39$21,311
Tresiba Flextouch U-200Insulin Degludec17$20,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,258
MounjaroTirzepatide17$19,603
EntrestoSacubitril/Valsartan19$16,448
LinzessLinaclotide11$12,846
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$12,096
TrulicityDulaglutide11$11,936
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$10,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$57$185,194154 claims
Novo NordiskOzempic$301$138,911129 claims
MerckJanuvia$155$96,26483 claims
Astellas Pharma US IncMyrbetriq$164$41,73454 claims
GSKTrelegy Ellipta, Anoro Ellipta$282$32,35433 claims
Lilly USA, LLCMounjaro, Trulicity$162$31,53928 claims
AbbVieLinzess, Synthroid$54$18,01371 claims
NovartisEntresto$78$16,44819 claims
AstraZenecaSymbicort$296$5,81620 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$4,531448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Huntsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →